V. Sandhu

发表

Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia

E. Estey, B. Wood, J. Pagel, 2015, Haematologica.

A phase I/II study of oral clofarabine plus low‐dose cytarabine in previously treated acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients at least 60 years of age

E. Estey, B. Wood, J. Pagel, 2015, British journal of haematology.

The effects of age, seropositivity and disease duration on autonomic cardiovascular reflexes in patients with rheumatoid arthritis

S. Allen, V. Sandhu, S. C. Allen, 2004, International journal of clinical practice.

Time spent in complete remission (CR) and overall survival (OS) in AML patients.

V. Sandhu, 2014 .

Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy

E. Estey, J. Abkowitz, F. Appelbaum, 2015, Leukemia.

Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia

E. Estey, B. Sandmaier, F. Appelbaum, 2015, Haematologica.

Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

E. Estey, M. Othus, R. Walter, 2016, Leukemia & lymphoma.

Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.

I. Bernstein, E. Estey, F. Appelbaum, 2016, The Lancet. Haematology.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high‐risk MDS

E. Estey, B. Wood, J. Singer, 2016, British journal of haematology.

Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission

E. Estey, M. Bar, B. Wood, 2015, Leukemia & lymphoma.

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.

E. Estey, J. Abkowitz, B. Wood, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of acquired copy‐neutral loss of heterozygosity in acute myeloid leukemia

E. Estey, B. Storer, F. Appelbaum, 2015, Cancer.

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.

E. Estey, M. Sorror, B. Sandmaier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

E. Estey, J. Pagel, R. Walter, 2015, American journal of hematology.

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

E. Estey, F. Appelbaum, J. Pagel, 2014, British Journal of Haematology.

The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia.

E. Estey, F. Appelbaum, J. Pagel, 2013, Blood.